Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06865079 · ClinicalTrials.gov registry record · Phase 2

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

A Phase 2 study of Osteoarthritis (OA) of the Knee, sponsored by OrthoTrophix.

Active
Registry status
Phase 2
Development phase
270
Enrollment target
20
Study locations

NCT06865079: Active Phase 2 study of Osteoarthritis (OA) of the Knee, sponsored by OrthoTrophix.

NCT06865079 is a Phase 2 study of Osteoarthritis (OA) of the Knee that is active but no longer recruiting, run by OrthoTrophix. The registered enrollment target is 270 participants, below the 1,380-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06865079, a Phase 2 study of Osteoarthritis (OA) of the Knee, is active but no longer recruiting, sponsored by OrthoTrophix.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Primary Outcome

CTC 5.0, also known as Common Terminology Criteria for Adverse/Serious Adverse Events version 5.0, is an extensively used classification system for assessing drug toxicity. This system categorizes drug toxicity into five levels: Grade 0, Grade 1, Grade 2, Grade 3, and Grade 4.

Interventions

  • DRUG TPX-100 200mg, Once weekly for 4 weeks
  • OTHER PBS

Study Locations (20)

California

  • Legent Orthopedic Hospital - Carrolton
  • Medvin Clinical Research - Covina
  • CORE Orthopaedic Medical Center - Encinitas
  • Marvel Clinical Research (Elite Clinical Network) - Huntington Beach
  • Medvin Clinical Research Center - Riverside
  • Medvin Clinical Research Center - Tujunga
  • Medvin Clinical Research Center - Whittier

Florida

  • K2 Medical Research - Maitland
  • Wellness Research Center - Miami
  • Well Pharma Medical Research - Miami
  • Las Mercedes Medical Research - Miami

Arizona

  • Elite Clinical Network - Scottsdale
  • Noble Clinical Research - Tucson

Kansas

  • AMR Kansas City - Kansas City
  • University of Kansas Medical Center - Kansas City

Georgia

  • Drug Studies of America - Marietta

Kentucky

  • AMR Lexington - Lexington

Louisiana

  • Accurate Clinical Research Inc. - Lake Charles

Minnesota

  • Mayo Clinic (Rochester) - Rochester

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2025-05-09
Est. Completion 2027-04-15
Phase Phase 2
OrthoTrophix

3 total trials

What the registry record for NCT06865079 still lists

NCT06865079 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 1,380-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Osteoarthritis (OA) of the Knee appearing as the primary indexed condition, and to 2 interventions - of which TPX-100 200mg, Once weekly for 4 weeks is the first listed.

NCT06865079 names 20 study sites across 9 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06865079 about?

NCT06865079 is a clinical study titled "53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee". 53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

What is the current status of trial NCT06865079?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2025-05-09. Estimated completion is 2027-04-15.

What conditions does trial NCT06865079 study?

This clinical trial studies the following conditions: Osteoarthritis (OA) of the Knee.

What interventions are being tested in trial NCT06865079?

The interventions under investigation include: TPX-100 200mg, Once weekly for 4 weeks (DRUG), PBS (OTHER).

Who is sponsoring clinical trial NCT06865079?

This trial is sponsored by OrthoTrophix, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06865079 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis (OA) of the Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06865079's enrollment target sits among peer trials

270 2nd of 8 the highest of 8 other Osteoarthritis (OA) of the Knee trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis (OA) of the Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06865079, the US trial registry maintained by the National Library of Medicine. NCT06865079 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.